SCHEMBL5558586

SCHEMBL5558586

O=C1NNCC2CCCC=C12

nearest known ligand 0.39

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10412758 0.88 MAPT (0.30) MAPT
SCHEMBL10718713 0.82 MAPT (0.40) MAPT
SCHEMBL3699545 0.75
SCHEMBL11593833 0.74
SCHEMBL1936488 0.73 MAPT (0.39) MAPT
SCHEMBL11195552 0.72 MAPT (0.45) MAPT
Chloroform SCHEMBL1937049 0.68 MAPT (0.35) MAPT
SCHEMBL900953 0.65 MAPT (0.70) MAPT
SCHEMBL6911275 0.65 MAPT (0.59) MAPT
SCHEMBL8686787 0.64 KDM1A (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220746-B2 Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors ALTANA PHARMA AG (DE) 2007-05-22 US disclosed
EP-1537100-B1 PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2007-04-25 EP disclosed
US-20060160813-A1 Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors ALTANA PHARMA AG (DE) 2006-07-20 US disclosed
EP-1537100-A1 PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
WO-2004018449-A1 PIPERIDINE-DERIVATIVES AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-04 WO disclosed
WO-2004018457-A1 PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-04 WO disclosed
EP-1042319-A1 DIHYDROBENZOFURANS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2000-10-11 EP disclosed
WO-1999031090-A1 DIHYDROBENZOFURANS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1999-06-24 WO disclosed
EP-0625978-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1994-11-30 EP disclosed
EP-0117403-B1 6-(ACYLAMINOARYL)-3(2H)-PYRIDAZINONE DERIVATIVES, THEIR PREPARATION AND USE BASF Aktiengesellschaft (DE) 1988-06-01 EP disclosed
EP-0117403-A1 6-(Acylaminoaryl)-3(2H)-pyridazinone derivatives, their preparation and use BASF Aktiengesellschaft (DE) 1984-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160813-A1 Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors PDE4A, PDE4B, PDE3B MAPT 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.